Skip to main content
Erschienen in: Current Infectious Disease Reports 5/2012

01.10.2012 | Sepsis (J Russell, Section Editor)

Immune Aspects of Sepsis and Hope for New Therapeutics

verfasst von: Steven P. LaRosa, Steven M. Opal

Erschienen in: Current Infectious Disease Reports | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Marked alterations of the innate and adaptive immune response follow invasive infection and generalized inflammatory states. If left unchecked, this state of immune dysregulation contributes to a myriad of maladaptive cellular responses that culminate in multiple organ dysfunction, septic shock, and lethality. The molecular details of the cell-signaling networks that underlie the pathophysiology of systemic inflammation and sepsis are now increasingly well understood. While a vigorous and effective immune response to invasive pathogens is essential for microbial clearance and host survival, nonresolving, generalized inflammation can induce diffuse endovascular damage, increased capillary permeability, coagulopathy, and widespread tissue damage. Current evidence indicates that a state of relative immune suppression often accompanies sepsis and might provide novel therapeutic options in some patients. An expanding number of potential therapeutic options are now in clinical development to reestablish control and promote resolution over sepsis-induced systemic inflammation and organ dysfunction.
Literatur
1.
Zurück zum Zitat van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis. 2008;8:32–43.PubMedCrossRef van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis. 2008;8:32–43.PubMedCrossRef
2.
Zurück zum Zitat Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a Primer. Crit Care Med. 2009;37(1):291–304.PubMedCrossRef Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a Primer. Crit Care Med. 2009;37(1):291–304.PubMedCrossRef
3.
Zurück zum Zitat •• Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. J Exp Med. 2011. doi:10.1084/jem.20111354. This large study clearly demonstrates that the genes altered in acute systemic inflammation following severe injury follow similar patterns of upregulation and down regulation in patients that survive and those that do not survive. The differences in gene expression between survivors and non-survivors are primarily quantitative and not qualitative differences. •• Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. J Exp Med. 2011. doi:10.​1084/​jem.​20111354. This large study clearly demonstrates that the genes altered in acute systemic inflammation following severe injury follow similar patterns of upregulation and down regulation in patients that survive and those that do not survive. The differences in gene expression between survivors and non-survivors are primarily quantitative and not qualitative differences.
4.
Zurück zum Zitat • Netea MG, van der Meer JWM. Immunodeficiency and genetic defects of pattern recognition receptors. N Engl J Med. 2011;464(1):60–70. This is an excellent review of the current state of knowledge about pattern recognition receptors, their microbial ligands, and the innate immune response to invasive pathogens. • Netea MG, van der Meer JWM. Immunodeficiency and genetic defects of pattern recognition receptors. N Engl J Med. 2011;464(1):60–70. This is an excellent review of the current state of knowledge about pattern recognition receptors, their microbial ligands, and the innate immune response to invasive pathogens.
5.
Zurück zum Zitat Rathinam VAK, Jiang Z, Waggoner SN, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol. 2010;11(5):395–403.PubMedCrossRef Rathinam VAK, Jiang Z, Waggoner SN, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol. 2010;11(5):395–403.PubMedCrossRef
6.
Zurück zum Zitat Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell. 2010;140:845–58.PubMedCrossRef Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell. 2010;140:845–58.PubMedCrossRef
8.
Zurück zum Zitat Beutler B. Inferences, questions and possibilities in toll-like receptor signaling. Nature. 2004;430:257–63.PubMedCrossRef Beutler B. Inferences, questions and possibilities in toll-like receptor signaling. Nature. 2004;430:257–63.PubMedCrossRef
9.
Zurück zum Zitat Visvanathan K, Charles A, Bannan J, Pugach P, Kashfi K, Zabriskie J. Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun. 2001;69:875–84.PubMedCrossRef Visvanathan K, Charles A, Bannan J, Pugach P, Kashfi K, Zabriskie J. Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun. 2001;69:875–84.PubMedCrossRef
10.
Zurück zum Zitat • Arad G, Levy R, Nasie I, et al. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biology. 2011;9:e1001149. This study elucidates the mechanism by which superantigens trigger the release of inflammatory cytokines resulting in septic shock.PubMedCrossRef • Arad G, Levy R, Nasie I, et al. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biology. 2011;9:e1001149. This study elucidates the mechanism by which superantigens trigger the release of inflammatory cytokines resulting in septic shock.PubMedCrossRef
11.
Zurück zum Zitat Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother. 2006;58(1):117–24.PubMedCrossRef Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother. 2006;58(1):117–24.PubMedCrossRef
12.
Zurück zum Zitat Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10:222–8.PubMedCrossRef Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10:222–8.PubMedCrossRef
13.
Zurück zum Zitat Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296(5574):1880–2.PubMedCrossRef Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296(5574):1880–2.PubMedCrossRef
14.
Zurück zum Zitat Coughlin SR. Thrombin signaling and protease-activated receptors. Nature. 2000;407(6801):258–64.PubMedCrossRef Coughlin SR. Thrombin signaling and protease-activated receptors. Nature. 2000;407(6801):258–64.PubMedCrossRef
15.
Zurück zum Zitat Tressel SL, Kaneider NC, Foley C, et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med. 2011;3:1–15.CrossRef Tressel SL, Kaneider NC, Foley C, et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med. 2011;3:1–15.CrossRef
16.
Zurück zum Zitat Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138–50.PubMedCrossRef Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138–50.PubMedCrossRef
17.
Zurück zum Zitat • Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. Tilting toward immunosuppression. Nat Med. 2009;15(5):496–7. This is a superb review of the problem of sepsis-induced immune suppression and the potential therapeutic options to restore immune function in these vulnerable patients.PubMedCrossRef • Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. Tilting toward immunosuppression. Nat Med. 2009;15(5):496–7. This is a superb review of the problem of sepsis-induced immune suppression and the potential therapeutic options to restore immune function in these vulnerable patients.PubMedCrossRef
18.
Zurück zum Zitat Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol. 2006;6:813–22.PubMedCrossRef Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol. 2006;6:813–22.PubMedCrossRef
19.
Zurück zum Zitat Hotchkiss RS, Opal SM. Immunotherapy for sepsis-A new approach against an ancient foe. N Engl J Med. 2010;361(1):87–9.CrossRef Hotchkiss RS, Opal SM. Immunotherapy for sepsis-A new approach against an ancient foe. N Engl J Med. 2010;361(1):87–9.CrossRef
20.
Zurück zum Zitat •• Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594–605. This study provides compelling pathologic and immunologic evidence that sepsis-induced immune suppression is commonplace in septic patients and the dominant finding in human lethal septic shock.PubMedCrossRef •• Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594–605. This study provides compelling pathologic and immunologic evidence that sepsis-induced immune suppression is commonplace in septic patients and the dominant finding in human lethal septic shock.PubMedCrossRef
22.
Zurück zum Zitat Newell MK, Tobin RP, Cabrera JH, et al. TLR-mediated B cell activation results in ectopic CLIP expression that promotes B cell-dependent inflammation. J Leuk Biol. 2010;88:779–89.CrossRef Newell MK, Tobin RP, Cabrera JH, et al. TLR-mediated B cell activation results in ectopic CLIP expression that promotes B cell-dependent inflammation. J Leuk Biol. 2010;88:779–89.CrossRef
23.
Zurück zum Zitat •• Nathan C, Ding A. Non-resolving inflammation. Cell. 2010;140:871–82. This is an excellent review of the critical elements that regulate the host response to human septic and sterile inflammatory processes. The mechanisms of immune and tissue-specific restoration of structure and function are examined in detail.PubMedCrossRef •• Nathan C, Ding A. Non-resolving inflammation. Cell. 2010;140:871–82. This is an excellent review of the critical elements that regulate the host response to human septic and sterile inflammatory processes. The mechanisms of immune and tissue-specific restoration of structure and function are examined in detail.PubMedCrossRef
24.
Zurück zum Zitat Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med. 2006;354(11):1166–76.PubMedCrossRef Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med. 2006;354(11):1166–76.PubMedCrossRef
25.
Zurück zum Zitat Kasten KR, Tschop J, Adediran SG, Hideman DA, Caldwell CC. T cells are potent early mediators of the host response to sepsis. Shock. 2010;34(4):327–36.PubMedCrossRef Kasten KR, Tschop J, Adediran SG, Hideman DA, Caldwell CC. T cells are potent early mediators of the host response to sepsis. Shock. 2010;34(4):327–36.PubMedCrossRef
26.
Zurück zum Zitat Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2010;107:1170–84.PubMedCrossRef Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2010;107:1170–84.PubMedCrossRef
27.
Zurück zum Zitat Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6:1191–7.PubMedCrossRef Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6:1191–7.PubMedCrossRef
28.
Zurück zum Zitat Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007; 869-74. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007; 869-74.
29.
Zurück zum Zitat • Ballina-Rosas M, Olofsson PS, Ochanni M, et al. Acetylcholine-synthesizing T Cells relay neural signals in a vagus nerve circuit. Science. 2011;334:98–101. This work points out the intricate interactions between Vagus nerve signals and anti-inflammatory signals within the spleen that regulate cellular immune function.CrossRef • Ballina-Rosas M, Olofsson PS, Ochanni M, et al. Acetylcholine-synthesizing T Cells relay neural signals in a vagus nerve circuit. Science. 2011;334:98–101. This work points out the intricate interactions between Vagus nerve signals and anti-inflammatory signals within the spleen that regulate cellular immune function.CrossRef
30.
Zurück zum Zitat • Wong CHY, Jenne CN, Lee W-Y, Léger C, Kubes P. Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. Science. 2011;334:101–5. This remarkable study identifies the role of the sympathetic nervous system in regulating the function of NKT cells and the important contribution of these uncommon T cells to bacterial clearance.PubMedCrossRef • Wong CHY, Jenne CN, Lee W-Y, Léger C, Kubes P. Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. Science. 2011;334:101–5. This remarkable study identifies the role of the sympathetic nervous system in regulating the function of NKT cells and the important contribution of these uncommon T cells to bacterial clearance.PubMedCrossRef
31.
Zurück zum Zitat Mattsby-Baltzer I, Bergstrom T, McCrea K, et al. Affinity aphaeresis for treatment of bacteremia caused by Staphylococcus aureus and/or methicillin-resistant S. aureus (MRSA). J Microbiol Biotechnol. 2011;21(6):659–64.PubMed Mattsby-Baltzer I, Bergstrom T, McCrea K, et al. Affinity aphaeresis for treatment of bacteremia caused by Staphylococcus aureus and/or methicillin-resistant S. aureus (MRSA). J Microbiol Biotechnol. 2011;21(6):659–64.PubMed
32.
Zurück zum Zitat • Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of Polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47. This is a well performed meta-analysis of the randomized and non-randomized studies of the Polymyxin B immobilized filter. These results are the basis for the need for adequately powered, randomized, controlled clinical trial.PubMedCrossRef • Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of Polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47. This is a well performed meta-analysis of the randomized and non-randomized studies of the Polymyxin B immobilized filter. These results are the basis for the need for adequately powered, randomized, controlled clinical trial.PubMedCrossRef
33.
Zurück zum Zitat Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock, the EUPHAS randomized controlled trial. JAMA. 2009;301:2445–52.PubMedCrossRef Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock, the EUPHAS randomized controlled trial. JAMA. 2009;301:2445–52.PubMedCrossRef
34.
Zurück zum Zitat Poelstra K, Bakker WW, Klok PA, et al. Dephosphorylation of endotoxin by alkaline phophatase in vivo. Am J Pathol. 1997;151:1163–9.PubMed Poelstra K, Bakker WW, Klok PA, et al. Dephosphorylation of endotoxin by alkaline phophatase in vivo. Am J Pathol. 1997;151:1163–9.PubMed
35.
Zurück zum Zitat Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229–65.PubMedCrossRef Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229–65.PubMedCrossRef
36.
Zurück zum Zitat Verweij WR, Bentala H, van der Vlag AH, et al. Protection against an Escherichia coli- induced sepsis by alkaline phosphatase in mice. Shock. 2004;22:174–9.PubMedCrossRef Verweij WR, Bentala H, van der Vlag AH, et al. Protection against an Escherichia coli- induced sepsis by alkaline phosphatase in mice. Shock. 2004;22:174–9.PubMedCrossRef
37.
Zurück zum Zitat Van Veen SQ, van Vliet AK, Wulferink M, et al. Bovine intestinal alkaline phosphatase attenuates the inflammatory response in secondary peritonitis in mice. Infect Immun. 2005;73:4309–14.PubMedCrossRef Van Veen SQ, van Vliet AK, Wulferink M, et al. Bovine intestinal alkaline phosphatase attenuates the inflammatory response in secondary peritonitis in mice. Infect Immun. 2005;73:4309–14.PubMedCrossRef
38.
Zurück zum Zitat Heemskerk S, Masereeuw R, Moesker O, et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med. 2009;37:417–23.PubMedCrossRef Heemskerk S, Masereeuw R, Moesker O, et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med. 2009;37:417–23.PubMedCrossRef
39.
Zurück zum Zitat • Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care. 2012;16:R14. This recently completed trial of alkaline phosphatase suggests that the benefit may be due to nephroprotective properties.PubMedCrossRef • Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care. 2012;16:R14. This recently completed trial of alkaline phosphatase suggests that the benefit may be due to nephroprotective properties.PubMedCrossRef
40.
Zurück zum Zitat Teleman D, Chung CS, Ayala A, et al. AB103, a CD28 antagonist peptide: a new therapeutic agent in a model of severe sepsis. Crit Care. 2011;15(3):35.CrossRef Teleman D, Chung CS, Ayala A, et al. AB103, a CD28 antagonist peptide: a new therapeutic agent in a model of severe sepsis. Crit Care. 2011;15(3):35.CrossRef
41.
Zurück zum Zitat Rice TW, Wheeler AP, Morris PE, et al. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine Fab for injection (CytoFab) in severe sepsis. Crit Care Med. 2006;34:2271–81.PubMedCrossRef Rice TW, Wheeler AP, Morris PE, et al. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine Fab for injection (CytoFab) in severe sepsis. Crit Care Med. 2006;34:2271–81.PubMedCrossRef
42.
Zurück zum Zitat Yang H, Feldser H, Zhang W, et al. SIRT1 activators promote p65 deacetylation and suppress TNFα stimulated NF-κB activation. Abstract presented at the 2011 ASBMB Meeting in Washington D.C. in April 2011. Yang H, Feldser H, Zhang W, et al. SIRT1 activators promote p65 deacetylation and suppress TNFα stimulated NF-κB activation. Abstract presented at the 2011 ASBMB Meeting in Washington D.C. in April 2011.
44.
Zurück zum Zitat Zingarelli B, Cook JA. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock. 2005;23:393–9.PubMedCrossRef Zingarelli B, Cook JA. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock. 2005;23:393–9.PubMedCrossRef
45.
Zurück zum Zitat Collin M, Murch O, Thiemermann C. Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia. Crit Care Med. 2006;34:1131–8.PubMedCrossRef Collin M, Murch O, Thiemermann C. Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia. Crit Care Med. 2006;34:1131–8.PubMedCrossRef
46.
Zurück zum Zitat Kaplan JM, Denenberg A, Monaco M, et al. Changes in peroxisome proliferator-activated receptor-gamma activity in children with septic shock. Intensive Care Med. 2010;36:123–30.PubMedCrossRef Kaplan JM, Denenberg A, Monaco M, et al. Changes in peroxisome proliferator-activated receptor-gamma activity in children with septic shock. Intensive Care Med. 2010;36:123–30.PubMedCrossRef
47.
Zurück zum Zitat Kapoor A, Shintani Y, Collino M, et al. Protective role of peroxisome proliferator-activated receptor-β/б in septic shock. Am J Respir Crit Care Med. 2010;182:1506–15.PubMedCrossRef Kapoor A, Shintani Y, Collino M, et al. Protective role of peroxisome proliferator-activated receptor-β/б in septic shock. Am J Respir Crit Care Med. 2010;182:1506–15.PubMedCrossRef
48.
Zurück zum Zitat • Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa activated in adults with septic shock. N Engl J Med. 2012;366:2055–64. This follow up study with recombinant human activated protein C failed to replicate improved survival in treated patients as observed in the original phase 3 trial. This drug has been taken off the market as a result of this study.PubMedCrossRef • Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa activated in adults with septic shock. N Engl J Med. 2012;366:2055–64. This follow up study with recombinant human activated protein C failed to replicate improved survival in treated patients as observed in the original phase 3 trial. This drug has been taken off the market as a result of this study.PubMedCrossRef
49.
Zurück zum Zitat Mohri M, Sugimoto E, Sata M, et al. The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation–a comparison with other anticoagulants. Thromb Haemost. 1999;82:1687–93.PubMed Mohri M, Sugimoto E, Sata M, et al. The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation–a comparison with other anticoagulants. Thromb Haemost. 1999;82:1687–93.PubMed
50.
Zurück zum Zitat Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41.PubMedCrossRef Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41.PubMedCrossRef
51.
Zurück zum Zitat Bhole D, Stahl GL. Therapeutic potential of targeting the complement cascade in critical care medicine. Crit Care Med. 2003;31(1 Suppl):S97–104.PubMedCrossRef Bhole D, Stahl GL. Therapeutic potential of targeting the complement cascade in critical care medicine. Crit Care Med. 2003;31(1 Suppl):S97–104.PubMedCrossRef
52.
53.
Zurück zum Zitat • Taylor FB, Kinasewitz GT, Lupu F. Pathophysiology, staging and therapy of severe sepsis in baboon models. J Cell Mol Med. 2012;16(4):672–82. This recently completed animal model of sepsis elucidates a second stage in sepsis whereby organ failure may be mediated by complement activation.PubMedCrossRef • Taylor FB, Kinasewitz GT, Lupu F. Pathophysiology, staging and therapy of severe sepsis in baboon models. J Cell Mol Med. 2012;16(4):672–82. This recently completed animal model of sepsis elucidates a second stage in sepsis whereby organ failure may be mediated by complement activation.PubMedCrossRef
54.
Zurück zum Zitat Silasi-Mansat R, Zhu H, Popescu NI, et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood. 2010;116:1002–10.PubMedCrossRef Silasi-Mansat R, Zhu H, Popescu NI, et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood. 2010;116:1002–10.PubMedCrossRef
55.
Zurück zum Zitat Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. Nat Med. 1999;5:788–92.PubMedCrossRef Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. Nat Med. 1999;5:788–92.PubMedCrossRef
56.
Zurück zum Zitat Igonin AA, Protsenko DN, Gennadiy GM, et al. C1-esterase inhibitor infusion increases survival rates for patients with sepsis. Crit Care Med. 2012;40:770–7.PubMedCrossRef Igonin AA, Protsenko DN, Gennadiy GM, et al. C1-esterase inhibitor infusion increases survival rates for patients with sepsis. Crit Care Med. 2012;40:770–7.PubMedCrossRef
57.
Zurück zum Zitat Weaver JG, Rouse MS, Steckelberg JM, Badley AD. Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis. FASEB J. 2004;18:1185–91.PubMedCrossRef Weaver JG, Rouse MS, Steckelberg JM, Badley AD. Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis. FASEB J. 2004;18:1185–91.PubMedCrossRef
58.
Zurück zum Zitat Unsinger J, McGlynn M, Kasten KR, et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol. 2010;184:3768–79.PubMedCrossRef Unsinger J, McGlynn M, Kasten KR, et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol. 2010;184:3768–79.PubMedCrossRef
59.
Zurück zum Zitat Inoue S, Unsinger J, Davis CG, et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction and improves survival in sepsis. J Immunol. 201;184 (3):1401-1409. Inoue S, Unsinger J, Davis CG, et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction and improves survival in sepsis. J Immunol. 201;184 (3):1401-1409.
60.
Zurück zum Zitat Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010;88:233–40.PubMedCrossRef Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010;88:233–40.PubMedCrossRef
61.
Zurück zum Zitat Albring JC, Sandau MM, Rapaport AS, et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J Exp Med. 2010;207(12):2551–9.PubMedCrossRef Albring JC, Sandau MM, Rapaport AS, et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J Exp Med. 2010;207(12):2551–9.PubMedCrossRef
62.
Zurück zum Zitat Zhao G, Jin H, Li J, et al. PyNTTTTGT prototype oligonucleotide IMT504, a novel effective adjuvant of the FMDV DNA vaccine. Viral Immunol. 2009;22(2):131–8.PubMedCrossRef Zhao G, Jin H, Li J, et al. PyNTTTTGT prototype oligonucleotide IMT504, a novel effective adjuvant of the FMDV DNA vaccine. Viral Immunol. 2009;22(2):131–8.PubMedCrossRef
63.
Zurück zum Zitat Laporte R, Kohan A, Heitzmann J, et al. Pharmacological characterization of FE 202158, a novel, potent, selective, and short acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension. JPET. 2011;337(3):786–96.CrossRef Laporte R, Kohan A, Heitzmann J, et al. Pharmacological characterization of FE 202158, a novel, potent, selective, and short acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension. JPET. 2011;337(3):786–96.CrossRef
64.
Zurück zum Zitat • Cribbs S, Matthay MA, Martin GS. Stem cells in sepsis and acute lung injury. Crit Care Med. 2010;38:2379–85. An excellent review of the multiple mechanisms of action of adult human stem cells. The paper further summarizes the experience to date with adult stem cells in animal models of sepsis and acute lung injury.PubMedCrossRef • Cribbs S, Matthay MA, Martin GS. Stem cells in sepsis and acute lung injury. Crit Care Med. 2010;38:2379–85. An excellent review of the multiple mechanisms of action of adult human stem cells. The paper further summarizes the experience to date with adult stem cells in animal models of sepsis and acute lung injury.PubMedCrossRef
65.
Zurück zum Zitat Mei SHJ, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010;182:1047–57.PubMedCrossRef Mei SHJ, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010;182:1047–57.PubMedCrossRef
66.
Zurück zum Zitat Krasnodembskaya A, Samarani G, Song Y, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 2012; in press. Krasnodembskaya A, Samarani G, Song Y, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 2012; in press.
Metadaten
Titel
Immune Aspects of Sepsis and Hope for New Therapeutics
verfasst von
Steven P. LaRosa
Steven M. Opal
Publikationsdatum
01.10.2012
Verlag
Current Science Inc.
Erschienen in
Current Infectious Disease Reports / Ausgabe 5/2012
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-012-0276-2

Weitere Artikel der Ausgabe 5/2012

Current Infectious Disease Reports 5/2012 Zur Ausgabe

Sepsis (J Russell, Section Editor)

Management of Acute Renal Dysfunction in Sepsis

Sepsis (J Russell, Section Editor)

Cardiovascular Management of Septic Shock in 2012

Skin, Soft Tissue, Bone, and Joint Infections (N Safdar, Section Editor)

Septic Arthritis in the Native Joint

Skin, Soft Tissue, Bone, and Joint Infections (N Safdar, Section Editor)

Subcutaneous Fungal Infections

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.